Full-Time

Quality Systems Specialist

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

501-1,000 employees

Develops cortisol modulators for medical conditions

Compensation Overview

$86.3k - $101.5k/yr

Senior

San Carlos, CA, USA

This is a hybrid position, requiring on-site presence 3 days per week.

Category
Lab & Research
Life Sciences
Required Skills
Visio
Word/Pages/Docs
Zendesk
Excel/Numbers/Sheets
Requirements
  • Experience with Electronic quality systems (Veeva QualityDocs and Veeva QMS) and Learning Management Systems (ComplianceWire LMS)
  • Proficient in the use of MS Office applications (Excel, Word, Visio, Teams)
  • Excellent organizational skills and the ability to manage multiple competing tasks
  • Excellent communication skills with the ability to collaborate with a wide range of stakeholders in various departments
Responsibilities
  • Ability to promptly respond to email inquiries and user support questions using ticketing systems like Zendesk
  • Support the Quality Systems team on a variety of tasks or projects that span across document control, training, inspection management and other quality event modules (including but not limited to deviations, CAPAs, and change controls)
  • Assist with training attendance records and cataloging and filing activities, as well as uploading completed forms into the Learning Management System (LMS)
  • Assess training qualification materials, including but not limited to SOPs and work instructions, ensuring they are appropriately added into training curricula across various GxP departments
  • Organize, file, and catalog legacy-controlled records in Document Control’s cabinets
  • Assist with uploading and certifying documents into Veeva QualityDocs to align legacy processes with current ones
  • Provide support for Corcept’s continuous improvement efforts of the Quality Management System (QMS)
  • Identify and escalate gaps and discrepancies in controlled documents and the processes that govern them (e.g. document formatting, SOP style consistency, clear and concise wording, document change control, etc.)
  • Capture detailed meeting minutes, action items, and key decisions, and circulate
  • Assist in drafting internal communications for events and status reports
  • Coordinate and schedule lunch and learn training sessions, office hours, and other events
Desired Qualifications
  • BA/BS degree in a scientific/technical/engineering field
  • Minimum of 5 years of experience in pharmaceutical or life sciences organizations

Corcept Therapeutics develops cortisol modulators to help regulate cortisol levels in the body, focusing on serious medical conditions like Cushing's syndrome, which is caused by excessive cortisol. Their main product, Korlym (mifepristone), is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome patients. Corcept distinguishes itself from competitors by investing heavily in research and development of proprietary molecules and by supporting medical education for healthcare professionals and patients. The company's goal is to lead in cortisol modulation and improve treatment options for those affected by cortisol imbalances.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Menlo Park, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Corcept's stock is the best performing pharma stock in 2025.
  • The MOMENTUM trial could expand Corcept's market reach.
  • Recent investments show growing confidence in Corcept's future prospects.

What critics are saying

  • Securities fraud investigations could lead to legal and financial repercussions.
  • Teva's antitrust lawsuit may result in legal challenges.
  • Potential reputation damage from ongoing legal investigations.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche with few competitors.
  • Korlym is the first FDA-approved treatment for Cushing's syndrome.
  • Corcept has discovered over 1,000 selective cortisol modulators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

1%

2 year growth

-3%
Access News Wire
Mar 18th, 2025
Shareholders that lost money on Corcept Therapeutics Incorporated(CORT) should contact Levi & Korsinsky about Securities Fraud Investigation - CORT

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ:CORT) concerning possible violations of federal securities laws.

Stock Titan
Mar 10th, 2025
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Corcept Therapeutics (NASDAQ: CORT) has launched the MOMENTUM clinical trial to investigate the prevalence of endogenous hypercortisolism (Cushing's syndrome) in patients with resistant hypertension.

PR Newswire
Mar 3rd, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Insider Monkey
Feb 23rd, 2025
Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma Stock So Far in 2025

Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma stock So Far in 2025.

Investing.com
Dec 30th, 2024
Corcept files NDA for new Cushing's syndrome drug

Corcept introduced Korlym(R), the first FDA-approved treatment for Cushing's syndrome, in February 2012.